Danaher reports $870M Q2 2026 net earnings and raises guidance

• Danaher reported second-quarter 2026 net earnings of $870 million, up 60% year-over-year, equating to $1.23 per diluted share.
• The company experienced strong performance in its Life Sciences segment, citing mid-teens growth in bioprocessing orders.
• Danaher raised its full-year 2026 adjusted EPS guidance to $8.45–$8.60 following the earlier-than-anticipated completion of its Masimo acquisition.

Danaher (NYSE:DHR) released its financial results for the second quarter of 2026, reporting net earnings of $870 million, or $1.23 per diluted share.

This represents a 60% increase year-over-year, while non-GAAP adjusted diluted EPS rose 8% to $1.94.

Revenue for the quarter grew 5.5% to $6.3 billion.

Non-GAAP core revenue was up 3%, and 4.5% excluding respiratory testing.

Following the earnings release, Danaher's share price was trading around $184.94.

Management highlighted a strong quarter in the Life Sciences segment.

The company cited mid-teens growth in bioprocessing orders, despite some project timing effects on bioprocessing revenue.

Operating cash flow was robust at $1.5 billion, with non-GAAP free cash flow reaching $1.3 billion.

In strategic developments, Danaher completed its acquisition of Masimo earlier than anticipated.

As a result of the strong performance and acquisition timeline, the company raised its full-year 2026 adjusted EPS guidance to $8.45–$8.60 and expects non-GAAP core revenue growth of 3% to 4%.